Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.05% | 22.67% | 78.23% | 5.68% | -8.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.05% | 22.67% | 78.23% | 5.68% | -8.74% |
| Cost of Revenue | 39.81% | 22.95% | 7.72% | -- | -22.36% |
| Gross Profit | -54.86% | -22.96% | -4.73% | -- | 24.44% |
| SG&A Expenses | 31.07% | 32.29% | 1.87% | -- | -39.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.43% | 27.01% | 5.07% | 12.77% | -32.34% |
| Operating Income | -41.92% | -27.09% | -3.41% | -13.59% | 33.77% |
| Income Before Tax | -104.55% | 7.05% | 91.94% | -- | 1,448.82% |
| Income Tax Expenses | -214.32% | 284.98% | 614.21% | -- | 693.37% |
| Earnings from Continuing Operations | -104.07% | 3.19% | 87.11% | -- | 1,433.13% |
| Earnings from Discontinued Operations | 658.87% | 50.18% | 207.84% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 118.15% | 85.66% | 4.93% | -- | -28.47% |
| Net Income | -96.68% | 24.36% | 132.66% | -349.52% | 1,547.72% |
| EBIT | -41.92% | -27.09% | -3.41% | -13.59% | 33.77% |
| EBITDA | -42.81% | -29.73% | -4.01% | -14.27% | 33.45% |
| EPS Basic | -96.32% | 20.78% | 133.70% | -315.45% | 1,389.89% |
| Normalized Basic EPS | -19.54% | 29.20% | 52.67% | -- | 63.24% |
| EPS Diluted | -96.14% | 20.78% | 131.12% | -320.57% | 1,322.03% |
| Normalized Diluted EPS | -26.06% | 29.20% | 52.67% | -- | 65.15% |
| Average Basic Shares Outstanding | -9.73% | -4.51% | -3.10% | 12.64% | 12.23% |
| Average Diluted Shares Outstanding | -14.42% | -4.51% | -3.10% | 12.64% | 18.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
